Biofrontera AG 2018 AR2
The report highlights Biofrontera AG's financial and operational performance for the 2018 fiscal year, during which the company achieved a 76% increase in total revenue to over EUR 21 million, driven by strong sales of its skin cancer drug Ameluz in the US and Europe. Key milestones included listing on the US NASDAQ stock exchange, receiving European Commission approval for daylight photodynamic therapy (PDT), and upscaling production batches. The company expanded its workforce by 28% to 157 employees, with women representing 41.7% of management. Biofrontera also focused on drug safety, quality management, and clinical trials, while preparing for future growth through strategic acquisitions and research collaborations.
Company: Biofrontera AG
Sector: Manufacturing
Country: Germany
Year: 2018
Type: AR2
Pages: 100
Back to company
Biofrontera AG
Annual Report
The report highlights Biofrontera AG's financial and operational performance for the 2018 fiscal year, during which the company achieved a 76% increase in total revenue to over EUR 21 million, driven by strong sales of its skin cancer drug Ameluz in the US and Europe. Key milestones included listing on the US NASDAQ stock exchange, receiving European Commission approval for daylight photodynamic therapy (PDT), and upscaling production batches. The company expanded its workforce by 28% to 157 employees, with women representing 41.7% of management. Biofrontera also focused on drug safety, quality management, and clinical trials, while preparing for future growth through strategic acquisitions and research collaborations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Employees